Literature DB >> 20806435

Age-dependent eradication of Helicobacter pylori in Japanese patients.

Satoshi Mamori1, Akihiro Higashida, Fumiaki Kawara, Katsuhiro Ohnishi, Akihiko Takeda, Eri Senda, Cho Ashida, Hajime Yamada.   

Abstract

AIM: To determine the general risk factors affecting the failure rate of first-line eradication therapy in Japanese patients with Helicobacter pylori (H. pylori) infection.
METHODS: The present study enrolled 253 patients who had an H. pylori infection, underwent gastro-endoscopy, and were treated with H. pylori eradication therapy. Eradication therapy consisted of 30 mg lansoprazole plus 750 mg amoxicillin and 400 mg clarithromycin twice daily for 7 d. All of the patients underwent a 13C urea breath test at least 1 mo after the completion of eradication therapy. The current study investigated the independent factors associated with successful H. pylori eradication using a multiple logistic regression analysis.
RESULTS: The overall success rate in the patients was 85.8%. Among the general factors examined in the multivariate analyses, only having an age less than 50 years was found to be significantly associated with a poor response to H. pylori eradication. Moreover, side effects were the only clinical factors in the patients who were under 50 years of age that significantly influenced the poor response to H. pylori eradication.
CONCLUSION: H. pylori-positive elderly patients should undergo eradication therapy. In addition, it is necessary to improve H. pylori eradication therapy in younger patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20806435      PMCID: PMC2932922          DOI: 10.3748/wjg.v16.i33.4176

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

Review 2.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

3.  Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials.

Authors:  L Laine; M B Fennerty; M Osato; J Sugg; L Suchower; P Probst; J G Levine
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

4.  Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.

Authors:  X Calvet; J Ducons; L Bujanda; F Bory; A Montserrat; J P Gisbert
Journal:  Am J Gastroenterol       Date:  2005-08       Impact factor: 10.864

Review 5.  Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.

Authors:  P Malfertheiner; F Mégraud; C O'Morain; A P S Hungin; R Jones; A Axon; D Y Graham; G Tytgat
Journal:  Aliment Pharmacol Ther       Date:  2002-02       Impact factor: 8.171

6.  Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?

Authors:  Javier P Gisbert; Antonio Domínguez-Muñoz; Antonio Domínguez-Martín; Jose Luis Gisbert; Santiago Marcos
Journal:  Am J Gastroenterol       Date:  2005-09       Impact factor: 10.864

7.  2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study.

Authors:  Paolo Paoluzi; Federico Iacopini; Pietro Crispino; Francesco Nardi; Antonino Bella; Margherita Rivera; Pina Rossi; Maurizio Gurnari; Francesco Caracciolo; Maddalena Zippi; Roberta Pica
Journal:  Helicobacter       Date:  2006-12       Impact factor: 5.753

Review 8.  Evolution of Helicobacter pylori therapy from a meta-analytical perspective.

Authors:  Javier P Gisbert; Ramón Pajares; José María Pajares
Journal:  Helicobacter       Date:  2007-11       Impact factor: 5.753

9.  Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy.

Authors:  P Della Monica; A Lavagna; G Masoero; L Lombardo; L Crocellá; A Pera
Journal:  Aliment Pharmacol Ther       Date:  2002-07       Impact factor: 8.171

10.  Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication.

Authors:  Lorenzo Fuccio; Maria Eugenia Minardi; Rocco Maurizio Zagari; Diego Grilli; Nicola Magrini; Franco Bazzoli
Journal:  Ann Intern Med       Date:  2007-10-16       Impact factor: 25.391

View more
  8 in total

1.  Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients.

Authors:  Stefan Sorin Arama; Catalin Tiliscan; Cristina Negoita; Alexandru Croitoru; Victoria Arama; Carmen Marina Mihai; Florinel Pop; Amit Garg
Journal:  Gastroenterol Res Pract       Date:  2015-12-27       Impact factor: 2.260

2.  Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Ai Fujimoto; Hiroto Kinoshita; Shuntaro Yoshida; Yoshihiro Isomura; Akira Toyoshima; Takanori Kanai; Naohisa Yahagi; Osamu Toyoshima
Journal:  J Clin Biochem Nutr       Date:  2017-02-16       Impact factor: 3.114

3.  Clinical background factors affecting outcomes of Helicobacter pylori eradication therapy in primary care.

Authors:  Nozomi Yokota; Ryusuke Ae; Masaki Amenomori; Koji Kitagawa; Takuya Nakamura; Tetsuro Yokota; Kato Masato; Teppei Sasahara; Yuri Matsubara; Koki Kosami; Yoshikazu Nakamura
Journal:  J Gen Fam Med       Date:  2019-04-10

4.  Factors Affecting the Intraluminal Therapy for Helicobacter pylori Infection.

Authors:  Cheng-Yu Ho; Ting-Wen Liu; Yang-Sheng Lin; Yen-Po Chen; Ming-Jen Chen; Horng-Yuan Wang; Tai-Cherng Liou
Journal:  Microorganisms       Date:  2022-02-11

5.  Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone.

Authors:  Salvatore Tolone; Valeria Pellino; Giovanna Vitaliti; Angela Lanzafame; Carlo Tolone
Journal:  Ital J Pediatr       Date:  2012-10-31       Impact factor: 2.638

6.  Two-week triple therapy has a higher Helicobacter pylori eradication rate than 1-week therapy: A single-center randomized study.

Authors:  Jiaofeng Wang; Gansheng Zhang; Xiaona Hu; Ye Liu; Zhijun Bao; Yiqin Huang
Journal:  Saudi J Gastroenterol       Date:  2015 Nov-Dec       Impact factor: 2.485

7.  Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study).

Authors:  Ratha-Korn Vilaichone; Natsuda Aumpan; Thawee Ratanachu-Ek; Pornpen Gamnarai; Tomahisa Uchida; Lotay Tshering; Varocha Mahachai; Yoshio Yamaoka
Journal:  Asian Pac J Cancer Prev       Date:  2020-04-01

8.  Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.

Authors:  Yanbo Tang; Guodu Tang; Liying Pan; Hua Zhu; Shanmei Zhou; Zhaoyong Wei
Journal:  Sci Rep       Date:  2020-09-21       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.